Ecuador vs Northern Mariana Islands: Tuberculosis treatment success rate
Ecuador
72.0%
in 2023
Northern Mariana Islands
73.0%
in 2023
Ecuador rank
154th
Northern Mariana Islands rank
153rd
Tuberculosis treatment success rate over time
- Ecuador
- Northern Mariana Islands
How they compare
Northern Mariana Islands currently reports 73.0% against 72.0% in Ecuador, a difference of 1.0%.
The two have swapped places 6 times across 24 shared years of data; in 1997 it was Northern Mariana Islands ahead.
Ecuador ranks 154th and Northern Mariana Islands ranks 153rd of 206 countries.
Northern Mariana Islands has averaged higher in every one of the 4 decades both report.
Head to head by decade
| Decade | Ecuador | Northern Mariana Islands | Difference | Ahead |
|---|---|---|---|---|
| 1990s | 60.5% | 68.0% | 7.5% | Northern Mariana Islands |
| 2000s | 75.9% | 81.0% | 5.1% | Northern Mariana Islands |
| 2010s | 75.4% | 88.9% | 13.4% | Northern Mariana Islands |
| 2020s | 70.5% | 82.5% | 12.0% | Northern Mariana Islands |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher tuberculosis treatment success rate, Ecuador or Northern Mariana Islands?
- Northern Mariana Islands, at 73.0% against 72.0% in Ecuador as of 2023.
- What is the difference in tuberculosis treatment success rate between Ecuador and Northern Mariana Islands?
- 1.0%, with Northern Mariana Islands ahead.
- How many years of comparable data are there for Ecuador and Northern Mariana Islands?
- 24 years are reported by both, from 1997 to 2023.
- How do Ecuador and Northern Mariana Islands rank globally for tuberculosis treatment success rate?
- Ecuador ranks 154th and Northern Mariana Islands ranks 153rd of 206 countries.
- Where does this data come from?
- WHO (2025) β with minor processing by Our World in Data, published as Tuberculosis treatment success rate. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Treatment success rate among new and relapse cases.